抗血管生成药治疗非小细胞肺癌

{:soso_e179:}谢谢老马，受益匪浅，收藏了

好帖，赞一个{:soso_e179:}

哈哈，谢谢啊，收到。

seacat 发表于 2013-3-17 17:44

                               
登录/注册后可看大图

阿西的确是目前最靠谱的V靶点药。

和其他比，阿西效果比较好？副作用比较小？
阿西副作用是高血压，我妈妈本来就有高血压。这种情况适合用吗？
我妈妈现在准备用2992，目前不需要用这类药，我先学习一下，提前准备。

学习了，谢谢老马

收藏，谢谢老马

bless 发表于 2013-9-2 23:39

                               
登录/注册后可看大图

和其他比，阿西效果比较好？副作用比较小？
阿西副作用是高血压，我妈妈本来就有高血压。这种情况适合用 ...

阿西有效率比较高，副作用虽然比多吉美、索坦小，但比起凡德、TIVO还是厉害。

你妈妈高血压的病因是什么？血压控制得怎样？最好还是咨询一下医生意见。

收藏好贴，感谢

学习了，受益匪浅，老马辛苦了

http://www.ncbi.nlm.nih.gov/pubmed/21617019
Ann Oncol. 2012 Mar;23(3):678-87. doi: 10.1093/annonc/mdr255. Epub 2011 May 26.
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B, Overbeck TR, Krissel H, Laurent D, Tiainen M, Commo F, Soria JC, Eberhardt WE.
Source
Department of Medicine, West German Tumor Center, University Hospital of University Duisburg-Essen, Germany. Thomas.gauler@uk-essen.de

Abstract
BACKGROUND:
The objective of this multicenter, prospective uncontrolled phase II trial was to determine efficacy, safety and tolerability of vatalanib, an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor receptors, in the second-line treatment of non-small-cell lung cancer (NSCLC).
PATIENTS AND METHODS:
Patients with stage IIIB/IV NSCLC-proven tumor progression during or after one platinum-based chemotherapy regimen received a fixed dose of 1250 mg vatalanib either once-daily dosing (QD) or two divided daily dosing (TDD: 500 mg a.m. + 750 mg p.m.) until disease progression or unacceptable toxicity. Primary end point was the disease control rate (DCR) at 12 weeks.
RESULTS:
Fifty-four and 58 patients were enrolled to the QD and TDD arms. DCR at 12 weeks was 35% in the QD and 37% in the TDD arm. The best overall response included one (2%) patient with confirmed partial response with QD and three (5%) with TDD. Median progression-free survival and overall survival were 2.1/7.3 months in the QD arm and 2.8/9.0 months with TDD arm. This therapy showed a moderate toxicity profile for the majority of patients.
CONCLUSIONS:
In the chosen patient population, vatalanib QD and TDD dosing demonstrated potential benefits in tumor size reduction, DCR, and survival.